Loading clinical trials...
Loading clinical trials...
Pregabalin Open-Label, Multicenter Add-On Trial Following a 4-Day Double-Blind Transition Period to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures.
To evaluate long-term safety and efficacy of pregabalin in patients with partial seizures.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Pfizer Investigational Site
Deakin, Australian Capital Territory, Australia
Pfizer Investigational Site
Chatswood, New South Wales, Australia
Pfizer Investigational Site
Westmead, New South Wales, Australia
Pfizer Investigational Site
Maroochydore, Queensland, Australia
Pfizer Investigational Site
Heidelberg, Australia
Pfizer Investigational Site
Woodville, Australia
Pfizer Investigational Site
Graz, Austria
Pfizer Investigational Site
Innsbruck, Austria
Pfizer Investigational Site
Duffel, Belgium
Pfizer Investigational Site
Helsinki, Finland
Start Date
October 1, 1998
Completion Date
November 1, 2005
Last Updated
January 1, 2007
325
Estimated participants
Pregabalin
DRUG
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions